

Vulvodynia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/V5F468E80750EN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: V5F468E80750EN

Abstracts

The 7 major vulvodynia markets reached a value of US\$ 4.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 6.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.84% during 2024-2034.

The vulvodynia market has been comprehensively analyzed in IMARC's new report titled "Vulvodynia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vulvodynia refers to a chronic pain condition that affects the vulva, which is the external female genitalia. The pain may be characterized as burning, stinging, or itching, and it can be constant or intermittent. The symptoms associated with this disease may be triggered by activities such as sex, tampon use, or even sitting for prolonged periods. Individuals suffering from vulvodynia may experience vaginal dryness, vulval inflammation, itching, sexual dysfunction, slightly inflamed or swollen vulvar tissue, painful intercourse, etc. These indications may vary from person to person and may last for months or years. The diagnosis of this ailment mainly depends on the evaluation of the patient's medical, sexual and surgical history, along with the identification of clinical features. The healthcare provider may also perform a pelvic examination to visualize the external genitals and vagina for indications of infection or other possible causes of the symptoms. Additionally, a colposcopy of the vulva is recommended, which uses a special magnifying glass to identify abnormalities in the affected regions and confirm a diagnosis among patients.

The rising incidences of nerve damage or irritation in the vulvar region on account of injury, surgery, trauma, etc., are primarily driving the vulvodynia market. In addition to this, the increasing prevalence of hormonal imbalances that can cause vulvar tissue to become thinner and more easily irritated, thereby leading to pain, is also bolstering the

market growth. Furthermore, the widespread adoption of effective drugs, including steroids, tricyclic antidepressants, anticonvulsants, etc., to help lessen chronic pain and stabilize the nerves is acting as another significant growth-inducing factor. Apart from this, the escalating demand for biofeedback therapy, owing to its numerous advantages, such as releasing pressure on the pelvic floor, relaxing tension and tightness, and improving quality of life in patients, is also creating a positive outlook for the market. Additionally, the emerging popularity of minimally invasive sympathetic nerve block techniques for treating this disease condition, since they can potentially manage pain and discomfort in women with minimal side effects, is expected to drive the vulvodynia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the vulvodynia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for vulvodynia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vulvodynia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the vulvodynia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the vulvodynia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vulvodynia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

Late-Stage Pipeline Drugs

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

Key Questions Answered in this Report:

Market Insights

How has the vulvodynia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the vulvodynia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the vulvodynia market across the seven major markets and

what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of vulvodynia across the seven major markets?

What is the number of prevalent cases (2018-2034) of vulvodynia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of vulvodynia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with vulvodynia across the seven major markets?

What is the size of the vulvodynia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of vulvodynia?

What will be the growth rate of patients across the seven major markets?

Vulvodynia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for vulvodynia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vulvodynia market?

What are the key regulatory events related to the vulvodynia market?

What is the structure of clinical trial landscape by status related to the vulvodynia market?

What is the structure of clinical trial landscape by phase related to the vulvodynia market?

What is the structure of clinical trial landscape by route of administration related to the vulvodynia market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 VULVODYNIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 VULVODYNIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 VULVODYNIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 VULVODYNIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 VULVODYNIA - UNMET NEEDS

10 VULVODYNIA - KEY ENDPOINTS OF TREATMENT

11 VULVODYNIA - MARKETED PRODUCTS

- 11.1 List of Vulvodinia Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 VULVODYNIA - PIPELINE DRUGS

12.1 List of Vulvodynia Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. VULVODYNIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. VULVODYNIA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 VULVODYNIA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Vulvodynia - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Vulvodynia - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Vulvodynia - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Vulvodynia - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Vulvodynia - Access and Reimbursement Overview

- 15.4 Market Scenario - Germany
 - 15.4.1 Vulvodynia - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Vulvodynia - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Vulvodynia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Vulvodynia - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Vulvodynia - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Vulvodynia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Vulvodynia - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Vulvodynia - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Vulvodynia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Vulvodynia - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Vulvodynia - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Vulvodynia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Vulvodynia - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Vulvodynia - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Vulvodynia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Vulvodynia - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Vulvodynia - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Vulvodynia - Access and Reimbursement Overview

16 VULVODYNIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 VULVODYNIA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 VULVODYNIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Vulvodynia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/V5F468E80750EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V5F468E80750EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

